Alteration of Genomic Responses to Doxorubicin and Prevention of MDR in Breast Cancer Cells by a Polymer Excipient: Pluronic P85
- 21 December 2005
- journal article
- research article
- Published by American Chemical Society (ACS) in Molecular Pharmaceutics
- Vol. 3 (2), 113-123
- https://doi.org/10.1021/mp050050g
Abstract
No abstract availableKeywords
This publication has 35 references indexed in Scilit:
- Strategies for reversing drug resistanceOncogene, 2003
- The dawning era of polymer therapeuticsNature Reviews Drug Discovery, 2003
- Micellar Nanocontainers Distribute to Defined Cytoplasmic OrganellesScience, 2003
- Inhibitors of vacuolar H+-ATPase impair the preferential accumulation of daunomycin in lysosomes and reverse the resistance to anthracyclines in drug-resistant renal epithelial cellsBiochemical Journal, 2003
- Cyclic AMP-dependent Transcriptional Up-regulation of Phosphodiesterase 4D5 in Human Airway Smooth Muscle Cells: IDENTIFICATION AND CHARACTERIZATION OF A NOVEL PDE4D5PROMOTERPublished by Elsevier BV ,2002
- Gene expression and amplification in breast carcinoma cells with intrinsic and acquired doxorubicin resistanceOncogene, 2001
- Interactions of Pluronic Block Copolymers with Brain Microvessel Endothelial Cells: Evidence of Two Potential Pathways for Drug AbsorptionBioconjugate Chemistry, 1997
- Cellular resistance to anthracyclinesGeneral Pharmacology: The Vascular System, 1996
- Hypersensitization of Multidrug Resistant Human Ovarian Carcinoma Cells by Pluronic P85 Block CopolymerBioconjugate Chemistry, 1996
- Induction of multiple-drug resistance during anti-neoplastic chemotherapyin vitroInternational Journal of Cancer, 1991